The pharmaceutical ingredients manufacturer Sudeep Pharma Limited is poised for its highly anticipated stock market debut this Friday, November 28. The company's equity shares will begin trading on both major Indian stock exchanges, marking a significant milestone for the pharmaceutical sector.
Key IPO Dates and Listing Details
The public offering opened for subscription from November 21 to November 25, with the allotment process completed on Wednesday, November 26. The Bombay Stock Exchange has officially confirmed that Sudeep Pharma shares will be listed and admitted for dealings on the exchange platform.
The company successfully raised ₹895 crore through this book-building issue, which comprised a fresh issue component of 16.02 lakh shares worth ₹95 crore and an offer-for-sale segment of 1.35 crore shares amounting to ₹800 crore. The price band for the IPO was set between ₹563 to ₹593 per share.
Overwhelming Market Response and Subscription Figures
Market data reveals an exceptionally strong response to the Sudeep Pharma public issue. The IPO was subscribed an impressive 93.72 times overall, demonstrating substantial investor confidence in the company's prospects.
The breakdown of subscription categories shows particularly robust demand from institutional investors. The Qualified Institutional Buyers segment was booked 213.08 times, while Non-Institutional Investors showed overwhelming interest with 116.72 times subscription. Retail Individual Investors participated actively with 15.65 times booking of their allocated portion.
Grey Market Premium Signals Strong Listing Gains
Ahead of the formal listing, the grey market activity indicates positive investor sentiment. Sudeep Pharma IPO GMP has reached ₹100 per share, according to market tracking sources. This substantial premium in the unlisted market suggests that shares are likely to debut at approximately ₹693 each, representing a nearly 15% premium over the upper end of the IPO price band at ₹593.
ICICI Securities served as the book running lead manager for the offering, while MUFG Intime India acted as the registrar for the IPO process. Market analysts are closely watching the listing performance, given the strong fundamentals of the pharmaceutical ingredients sector and the company's established market position.
